Arachidonic acid uptake by human platelets is mediated by CD36

Area of Science:

• Biochemistry
• Hematology
• Immunology

Background:

• Platelet activation is crucial for hemostasis and thrombosis.
• Arachidonic acid is a key mediator in platelet function.
• The role of specific receptors in arachidonic acid uptake is not fully elucidated.

Purpose of the Study:

• To investigate the involvement of glycoprotein (GP) IV (CD36) in arachidonic acid uptake by human platelets.
• To determine the effect of anti-CD36 monoclonal antibody (MAB) on arachidonic acid uptake and platelet activation.

Main Methods:

• Utilized anti-CD36 monoclonal antibody (MAB) to block CD36 function on human platelets.
• Measured the binding of radiolabeled arachidonic acid to MAB-treated and untreated platelets.
• Assessed arachidonic acid-induced and collagen-induced platelet aggregation and thromboxane A(2) synthesis.

Main Results:

• Anti-CD36 MAB significantly reduced the binding of [(14)C]arachidonic acid to platelets.
• The MAB inhibited arachidonic acid-induced platelet aggregation and thromboxane A(2) synthesis in a dose-dependent manner.
• Pre-incubation with MAB inhibited arachidonic acid-induced aggregation by 50% and collagen-induced aggregation by 7-8%, increasing lag time by 200%.

Conclusions:

• Platelet arachidonic acid uptake is mediated, at least in part, by CD36.
• CD36 plays a significant role in arachidonic acid-induced platelet activation.
• Targeting CD36 may offer a therapeutic strategy for modulating platelet function.